1	Usability of three blood-based HIV self-testing devices among men who have
2	sex with men and female sex workers in Yaounde and Douala, Cameroon
3	Awono Noah JP Yves <sup>1,6*</sup> , Justin Ndié <sup>1,6</sup> , Francis Ateba Ndongo <sup>1,8</sup> , Onesimus Yongwa <sup>2</sup> ,
4	Rogacien Kana <sup>1,6</sup> , Martial Bonyohe <sup>1</sup> , Plessy Hedgar Mboussam <sup>2</sup> , Tatiana Palisson Avang <sup>1</sup> ,
5	Fatima Moulioum <sup>1</sup> , Félicité Tabala Naah <sup>1</sup> , Gutenberg Tchikangni <sup>2</sup> , Audrey Djomo Nzaddi <sup>3</sup> ,
6	Alice Ketchaji <sup>4</sup> , Carelle Djofang Yepndo <sup>4</sup> , Gildas Nguemkam <sup>1</sup> , Charles Baudelaire Ndindjock
7	IV <sup>2</sup> , Brice Seukam <sup>2</sup> , Yagaï Bouba <sup>3</sup> , Ernest Désiré Mvilongo Anaba <sup>3</sup> , Rina Estelle Djoukwe <sup>5</sup> ,
8	Serge Billong <sup>4,7</sup> , Karin Hatzold <sup>10</sup> , Annie Michele Salla <sup>2</sup> , Jérôme Ateudjieu <sup>1,9</sup> , Anne Cécile
9	Zoung - Kanyi Bissek <sup>1,7</sup>
10	<sup>1-</sup> Operational Health Research Division/Ministry of Public Health, Cameroon
11	<sup>2-</sup> Cameroon Social Marketing Association, Cameroon
12	<sup>3-</sup> Central Technical Group/National AIDS Control Committee
13	<sup>4-</sup> Department of Disease Control, Epidemics and Pandemics/Ministry of Public Health
14	<sup>5-</sup> Directorate of Pharmacy, Medicines and Laboratories/Ministry of Public Health
15	6- Media Convergence Health Research Centre, Cameroon
16	7- University of Yaounde I, Faculty of Medicine and Biomedical Sciences, Cameroon
17	<sup>8-</sup> Faculty of Medicine, University of Garoua, Cameroon
18	9- Department of Public Health, University of Dschang, Cameroon
19	<sup>10-</sup> Population Services International
20	Corresponding author : Awono Noah Jean Pierre Yves ; Tel : +237 697641459
21	e.mail : <u>anjpy@live.fr</u> (ANJPY)
22	Competing interests: The authors have declared that no competing interests exist.
23	
24	
25	

# 26 Abstract

#### 27 Background

Blood-based HIV self-testing represents an alternative for increasing screening among key
populations or populations with difficult access. In Cameroon, very few studies, on the usability
of HIV self-tests based on blood samples, have been carried out among these groups.

#### 31 **Objective**

The aim of this study was to assess the usability of blood-based HIV self-testing among men who have sex with men (MSM) and female sex workers (FSWs) in the cities of Yaoundé and Douala, Cameroon.

#### 35 Materials and Methods

36 An observational study was conducted in 17 Community-Based Organisations (CBOs), including 10 MSM and 07 FSWs in Yaoundé and Douala from 11 to 22 June 2022. The study 37 population consisted of HCV and MSM aged 21 years and over who agreed to participate in 38 the study. After they were recruited consecutively in their respective CBOs, they received 39 counselling, unassisted HIV blood self-testing and condoms. Data was collected using an 40 administered questionnaire. Three HIV blood self-testing devices were used in the study: Mylan 41 HIV Self-Test, Sure Check HIV Test® (Chembio Diagnostics Inc), Check Now HIV Self-42 Test(Abbott<sup>™</sup> Point Of Care). Analysis was conducted using SPSS 23 software with a 95% 43 confidence level. 44

#### 45 **Results**

Of 817 participants who completed the HIV blood self-test, just over half were TS 459(56.2%);
the median age was 27 years (IQR: 22 years - 34 years) and the 25-49 age group was most
represented 482(59.0%). One participant in ten (10%) had never been tested for HIV. However,
98.6% of participants agreed to use the HIV blood self-test and the vast majority (97.1%)
followed the steps for carrying out the HIV blood self-test. An MSM was 4 times more likely

to pass an HIV blood self-test than a TS (aOR= 4.01; 95% CI: 1.181-13.625; p=0.026). 51 Similarly, TS and MSM who used the Abbott Check Now HIV Self-Test (aOR= 3.85; 95% CI: 52 1.246-11.908; p=0.019) and Chembio Sure Check HIV Test (aOR= 2.83; 95% CI: 1.072-7.720; 53 54 p=0.036) were respectively 3.8 and 2.8 times and more likely to pass their self-test than those who used the Mylan blood self-test. Agreement between a participant's HIV blood self-test 55 result and Abbott-trained investigator-observers was moderate ( $\kappa$ =0.485; CI95% (0.359-0.610); 56 p=0.001) while agreement with Chembio and Mylan was respectively low ( $\kappa$ =0.329; CI95% 57 (0.203-0.454); p=0.001) and very low ( $\kappa$ =0.194; CI95%(0.05-0.329); p=0.001). 58

## 59 **Conclusion**

HIV blood self-testing is acceptable and usable by key populations in Cameroon. Although usability was limited by problems in interpreting results and incorrect disposal of waste t by key populations, a blood-based HIV Self-Test, with moderate concordance, proved suitable for unassisted use in key populations, what could help improve HIV prevention interventions.

# 64 Introduction

In every region of the world, key populations -men who have sex with men (MSM), female sex 65 workers (FSWs), drug users and transgender people- and their partners are much more affected 66 by HIV infection than the general population. In sub-Saharan Africa specifically, key 67 populations and their partners accounted for 51% of new HIV infections in 2021. Given the 68 importance of MSM and MSM-attached populations, where routine HIV screening strategies 69 70 have produced mixed results, the WHO recommends implementing new strategies such as HIV 71 self-testing (HIVST) [1]. Hence the prequalification of the first salivary HIV self-testing kit by the WHO in 2017. The first HIV blood self-test was prequalified in 2019, followed by 4 other 72 73 blood self-tests between 2019 and 2022. In terms of institutional support, formal HIV self-74 testing regulations have existed in many African countries since 2017, whereas they are still being developed or even informal in other countries [2]. However, in sub-Saharan Africa, apart 75

from the Democratic Republic of the Congo (DRC), the Central African Republic (CAR) and 76 Benin, very few French-speaking countries have shown concern for blood-based HIV self-77 testing. In the DRC, evidence has been produced in favour of the feasibility and performance 78 79 of blood self-testing in the general [3] and key populations such as FSWs [4] or vulnerable populations such as adolescents [5]. In general, the majority of users were able to understand 80 the instructions for use, identify the different components of the self-test kit, perform the test 81 until a valid test was obtained, and good interpretation as well. Many of the advantages 82 highlighted by these studies, such as confidentiality, speed, and efficiency, were pointed out by 83 users, despite some difficulties encountered in using the lancet and misinterpreted results. These 84 studies suggest that blood self-testing could be considered as an additional self-testing option 85 for key populations. In Cameroon, in 2018, HIV prevalence in the general population (15-49 86 vears) was estimated at a rate of 2.7% [6]. The percentage among MSM and FSWs was 20.6% 87 and 24.3% respectively [7]. In addition to the burden of HIV, these populations are afraid of 88 stigmatisation and discrimination as a result of taking part in conventional HIV screening 89 programmes. A study conducted in Douala-Cameroon, has shown that only 48% of MSM had 90 already been exposed to HIV prevention interventions [8]. Some research carried on the 91 acceptability of salivary HIV self-tests among MSM and FSWs in Yaoundé, has shown a high 92 level of acceptability and has led to the adoption of salivary HIV self-testing among MSM and 93 FSWs in Cameroon [9]. If blood-based HIV self-tests are to be introduced in this country as a 94 complement to the already-approved saliva self-test, there must first of all be evidence of their 95 usability. To date, no locally conducted and published study has shed any light on this strategic 96 option. To sum up, the aim of this study was to assess the usability of HIV self-testing among 97 98 men who have sex with men and female sex workers in Yaoundé and Douala. The study included compliance with the steps involved in carrying out the HIV blood self-test and 99 interpreting the results. 100

# 101 Methodology

## 102 **Ethical considerations**

103 This protocol obtained a favourable opinion from the National Ethics Committee for 104 Human Health Research of Cameroon (reference numbers 2022/04/1448/CE/CNERSH/SP) and 105 from the Operational Health Research Division of the Ministry of Health of Cameroon 106 (Administrative Research Authorisation reference numbers 031-16-22). A written informed 107 consent was obtained from all participants. All data collected was treated confidentially and 108 stored within the limits permitted by law.

## 109 *Type of study*

A cross-sectional and observational study was conducted from 11 to 22 June 2022 in 17
community-based organisations (CBOs) in Yaoundé and Douala.

# 112 Selection of the study population

The study population consisted of MSM and FSWs, aged 21 years and over, declaring unknown HIV status or HIV-negative for more than three months, fluent in French and/or English and usually receiving HIV testing services offered by CBOs involved in the implementation of HIV control activities. Any participants who were on PrEP (pre-exposure prophylaxis) or antiretroviral treatment, had a known HIV-positive status and/or had extenuating conditions (e.g., acute illness) that might interfere with the study process were automatically excluded.

## 119 Site selection

The study was carried out in Cameroon, a Central African country with a population of around 25 million. The study was conducted in the two major Cameroonian cities namely Yaoundé (the capital city) and Douala (the economic capital). They were chosen because of the size of their Community-Based Organisations (CBOs), key populations and their high "hot spot" densities. In each study city, the CBOs were selected based on the size of the target effectively covered and the acceptance of the study by their leaders.

126 Sample size and sampling.

The sample size was calculated according to the criteria recommended by the WHO [10] taking into account the proportion of HIV testing observed in each target group in previous national or regional studies. The minimum sample size adjusted for the 15% non-response rate was estimated at 785 study participants (423 TS and 362 MSM), including 262 for each HIV selftesting device.

#### 132 **Recruitment of MSM and sex workers**

MSM were recruited by leader mothers, innkeepers, and gatekeepers in the community and in the hot spots. They were recruited consecutively until the planned sample size for each type of HIV blood self-test was reached. MSM were mobilised by peer educators and community leader fathers. They were also recruited consecutively until the planned sample size for each type of HIV blood self-test was reached.

## 138 Data collection

Data collection was carried out by a research team consisting of twenty healthcare staff who 139 had been trained to perform blood self-tests (laboratory technicians and nurses). The study ran 140 141 for 9 months from November 2021 to July 2022 and included eight (08) days of data collection 142 from 11 to 22 June 2022. In each CBO selected for the survey, a setting was set up to conduct the data collection and HIV blood self-test procedures in complete confidentiality. To begin 143 with, data collectors introduced themselves to every participant. After that authorisations for 144 the study were distributed and its purpose highlighted. Then, participants were given an 145 information leaflet and their informed consent was obtained. Information about their eligibility 146 for the study was also collected. Next, the blood self-test kit was given to the recruited 147 participant to carry out the blood self-test procedure under observation. The tests were done on 148 site and the results were reported by participants and two trained investigator-observers in a 149 150 row. CBO managers and staff provided pre- and post-test counselling to each participant. Once the self-testing process was complete, every investigator-observer carried on with the 151 administration of the questionnaire to one participant at atime. As there were no available 152

standardised questionnaires about the usability of HIV blood self-tests at the time of the study, 153 a product-specific semi-structured questionnaire was developed (Text S1) based on WHO 154 documentation on pregualification [11-13]. The questionnaire was tested with a sample of 43 155 156 participants (19 MSM and 24 FSWs) for each HIV self-test that had to be used. A semistructured questionnaire, set up on the tablets via the Kobo Collect application, was 157 administered by observers. The questionnaire included an observation checklist of the HIV self-158 testing process, test results, waste management and participants' experiences with the device 159 and instructions for use. The observer systematically provided post-test counselling and 160 condoms to study participants after they had completed the test and read the results. 161 MSM/FSWs with a reactive test were referred to their CBO's supervising health facility for 162 confirmation of their test result in accordance with the national algorithm for HIV testing and 163 management where appropriate. 164

#### 165 Type of blood-based Self-test devices

Three blood-based HIV Self-Testing (HIVST) devices were used in the study: Mylan® HIV
Self-Test (Atomo Diagnostics Pvty. Ltd), Sure Check® HIV Self-Test (Chembio Diagnostic
Systems, Inc), Check Now<sup>TM</sup> HIV Self-Test (Abbott Rapid Diagnostics Jena GmbH). Each HIV
Self-Test device included the manufacturer's instructions for use and other kit components. No
additional user aids, demonstrations or assistance were provided to participants.

## 171 Data processing and statistical analysis

After data was collected with the KoboCollect application deployed through the KoboToolbox platform, it was imported into SPSS (version 23) for analysis using descriptive statistics and multivariate regression models. For this study, usability of the blood self-test was defined as the proportion of MSM/STDs who were able to perform self-testing steps, interpret the result and dispose of the waste in exact compliance with the manufacturer's instructions. Variables that were statistically significant (p-value <0.05) in the univariate analysis were included in the multivariate logistic regression. Multivariate logistic regression analysis was used to identify

factors associated with successful self-testing. The results of the analysis are presented as 179 adjusted odds ratios (aOR) with 95% confidence intervals (CI) and interpreted as the odds of 180 successful completion of the self-test among non-professional users who have been exposed or 181 182 not to the associated factor. Variables included in the multivariable logistic regression analysis were city, type of key population, age, sex, education, employment, living status, ever HIV 183 tested, and type of blood based HIVST kit. Self-test success or self-test usability was calculated 184 as the percentage of participants who correctly performed the key steps and obtained an 185 interpretable result. Tests that did not produce a control line were identified as "Invalid" and 186 reported as a failure. 187

Agreement between reactive (positive) and non-reactive (negative) HIV self-test results was measured using Cohen's Kappa based on agreement rates between reactive and non-reactive self-test results interpreted by study participants and observing healthcare staff. This analysis excluded incomplete self-tests, invalid results interpreted by healthcare staff and inconclusive (uncertain) results interpreted by study participants.

193 **Results** 

# Demographic characteristics and HIV testing history of MSM and FSW

Of the 817 participants who agreed to be tested for HIV, 56.3% were living in the city of Douala; almost all of them were Cameroonian (98.2%); 56.2% were MSM; the median age was 27 years and the 25-49 age group was the most represented (59%); the majority of participants had completed secondary education (58.8%); the unemployed accounted for just under half of the sample (43.3%); the vast majority of participants were single (77.8%); one in ten participants (10%) had never been tested for HIV before the test was carried out as part of this study. A wide disparity between the two sub-populations was observed (17.9% of MSM 203 compared with 3.9% of MSM). 280 Chembio Sure Check HIV Test®, 272 Abbott™Check

Now HIV Self-Test and 265 Mylan® HIV Self-Test were used for this study (Table 1).

205	Table I : Distribution of TS and MSM according to sociodemographic characteristics and
206	HIV testing history.

Characteristics	Chembio Sure Check HIV Test®	Abbott™ Check Now HIV Self-Test	Mylan® HIV Self-Test	Total	
	n=280	n=272	n=265	n=817	
	n(%)	n(%)	n(%)	n(%)	
City					
Yaoundé	120(42.9)	118(43.4)	117(44.2)	355(43.5)	
Douala	160(57.1)	154(56.6)	148(55.8)	462(56.5)	
Nationality					
Foreign	6(2.1)	2(0.7)	7(2.6)	15(1.8)	
Cameroonian	274(97.9)	270(99.3)	258(97.4)	802(98.2)	
Population type					
SW	157(56.1)	127(46.7)	175(66.0)	459(56.2)	
MSM	123(43.9)	145(53.3)	90(34.0)	358(43.8)	
Age (in years)					
Median (IQR)	26.0(22-34)	26.5(22-32)	27.0(23-34)	27.0(22-34)	
21-24	118(42.1)	115(42.3)	85(32.1)	318(38.9)	
25-49	156(55.7)	153(56.3)	173(65.3)	482(59.0)	
50+	6(2.1)	4(1.5)	7(2.6)	17(2.1)	
Education					
Elementary and under	15(5.4)	10(3.7)	17(6.4)	42(5.1)	
Second level	162(57.9)	167(61.4)	151(57.0)	480(58.8)	
Advanced	103(36.8)	95(34.9)	97(36.6)	295(36.1)	
Employment status					
Self-employed	93(33.2)	88(32.4)	97(36.6)	278(34.0)	
Unemployed	124(44.3)	112(41.2)	118(44.5)	354(43.3)	
Employed in private sector	55(19.6)	67(24.6)	45(17.0)	167(20.4)	
Employed in public sector	8(2.9)	5(1.8)	5(1.9)	18(2.2)	
Marital status					
Single	216(77.1)	213(78.3)	206(78.0)	635(77.8)	
Divorced	11(3.9)	5(1.8)	9(3.4)	25(3.1)	
Widowed	3(1.1)	1(0.4)	4(1.5)	8(1.0)	
Cohabiting	28(10.0)	34(12.5)	32(12.1)	94(11.5)	
Married	22(7.9)	19(7.0)	13(4.9)	54(6.6)	
History of HIV testing	. /	· /	. /	. /	
Yes	255(91.1)	239(87.9)	241(90.9)	735(90.0)	
No	25(8.9)	33(12.1)	24(9.1)	82(10.0)	

# 207 Usability of the HIV blood self-test by study participants

The vast majority of participants (97.1%) followed the steps for performing the self-test; the errors commonly made while using the self-test were, in order of occurrence: incorrect volume of blood drawn (87.9%); insufficient collection/addition of blood to the well (29.9%), particularly with Chembio (39.3%) and Mylan (37.4%); failure to dispose of waste according to the leaflet (23.4%), particularly with Chembio (24.3%) and Mylan (27.5%); incorrect positioning of the self-test device (20.4%), particularly with Chembio (22.9%) and Mylan

#### 214 (28.7%) (Table 2).

Characteristics	Chembio® Sure Check HIV Self-Test	Abbott™ Check Now HIV Self-Test	Mylan® HIV Self-Test	Total
	n=279	n=272	n=263	n=814
	n(%)	n(%)	n(%)	n(%)
Completeness of self-test steps				
Success	273(97.8)	268(98.5)	249(94.7)	790(97.1)
Failure	6(2.2)	4(1.5)	14(5.3)	24(2.9)
Frequent errors made during self-				
testing process				
Incorrect volume of blood				
drawn (tube over/underfilled)	246(91.1)	226(86.9)	217(85.4)	689(87.9)
Insufficient blood collected/added to the well	110(39.3)	32(11.8)	99(37.4)	241(29.5)
Waste not disposed of in accordance with instructions	68(24.3)	50(18.4)	73(27.5)	191(23.4)
Incorrect positioning of the device	64(22.9)	27(9.9)	76(28.7)	167(20.4)

#### **Table II :** Ability to perform HIV self-testing in exact compliance with the leaflet

216

Regarding agreement in the interpretation of results between participants and the healthcare 217 workers trained as HIV testing counsellors, overall, the percentage of positive agreement was 218 219 90.9% and the percentage of negative agreement was 81.7%. The total percentage of agreement 220 was 82.3%. However, when controlling the random effect, this total percentage of agreement dropped to 35.1%, indicating low overall agreement ( $\kappa$ =0.351; 95% CI (0.274-0.427); 221 P=0.001). Notwithstanding, disparities were identified depending on the blood self-test device 222 used. Indeed, agreement between a participant's (MSM or TS) HIV blood self-test result and 223 investigator-observers trained with Abbott<sup>TM</sup> Check Now HIV Self-Test was moderate 224 (κ=0.485; 95% CI (0.359-0.610); P=0.001) while agreement with Chembio Sure Check HIV 225 Test® and Mylan® HIV Self-Test was respectively low ( $\kappa$ =0.329; 95% CI (0.203-0.454); 226 P=0.001) and very low ( $\kappa$ =0.194; 95% CI (0.05-0.329); P=0.001) with percentages of total 227 agreement corrected by the random effect of 32.9% and 19.4% (Table 3). 228

#### 229 Table III: Agreement between HIV blood self-test results interpreted respectively by

#### 230 participants trained health workers

Characteristics	Chembio Sure Check HIV Test®	Abbott™ Check Now HIV Self-Test	Mylan® HIV Self-Test	Total n=776	
	n=269	n=263	n=244		
Interpreted self-test results					
Positive agreement	17	25	8	50	
Negative agreement	201	198	190	589	
Positive disagreement	1	0	4	5	
Negative disagreement	50	40	42	132	
Percentage of agreement					
Ppositive agreement percentage	94.4%	100%	66.7%	90.9%	
Negative agreement percentage	80.1%	83.2%	81.9%	81.7%	
Total agreement percentage	81%	84.8%	81.1%	82.3%	
Cohen's Kappa (κ)	0.329	0.485	0.194	0.351	
95% CI of Cohen's Kappa (lb - ub)	(0.203-0.454)	(0.359-0.610)	(0.05-0.329)	(0.274-0.427)	
Р	0.001*	0.001*	0.001*	0.001*	

231 P: significance level; \*: <0.01; CI (95%): 95% confidence interval; lb : lower bound; ub: upper bound

#### 232 Factors associated with successful HIV blood self-testing

Multivariate logistic regression analysis (Table 4) showed a significant positive association 233 between successful self-testing with Abbott Check Now HIV Self-Test (aOR= 3.85; 95% CI: 234 1.246-11.908; p=0.019), Chembio Sure Check HIV Test (aOR= 2.83; 95% CI: 1.072-7.720; 235 p=0.036) and being MSM (aOR= 4.01; 95% CI: 1.181-13.625; p=0.026). Multivariable analysis 236 also confirmed a significant negative association between self-test success and the city of 237 residence (aOR = 0.27; 95% CI: 0.110-0.676). Age over 30 years, which was nearly negatively 238 associated with successful self-testing in the univariate analysis, was not confirmed in the 239 multivariate analysis after adjustment with other variables. In fact, MSM were 4 times more 240 likely to succeed in self-testing than an FSW. Similarly, FSW and MSM who used the Abbott 241 and Chembio blood self-test were respectively 3.8 and 2.8 times more likely to pass their test 242 than those who used the Mylan blood self-test. In addition, the probability of carrying out their 243 blood self-test successfully was 73% lower for participants living in the city of Yaoundé than 244 for those living in the city of Douala. 245

	Univariable analysis of self-test success			Multivariable analysis of self-test success					
	Ν	n(%)	B(SE)	Р	OR(IC95%)	B(SE)	Р	aOR (IC95%)	N2
City									814
Douala	462	454(98.3)			1			1	
Yaoundé	355	337(94.9)	-1.109**(0.431)	0.01	0.33(0.142-0.768)	-1.300*(0.463)	0.005	0.27(0.110-0.676)	
Type of population									
FSWs	459	437(95.2)			1			1	
MSM	358	354(98.9)	1.494*(0.548)	0.006	4.45(1.521-13.048)	1.389*(0.624)	0.026	4.01(1.181-13.625)	
Age									
Under 25	318	312(98.1)			1			1	
25 to 30 years old	232	225(97.0)	-0.481(0.563)	0.393	0.61(0.205-1.864)	-0.179(0.605)	0.768	0.83(0.255-2.739)	
Over 30	267	254(95.1)	-0.979(0.501)	0.051	0.34(0.117-0.972)	-0.540(0.551)	0.326	0.58(0.198-1.714)	
Education									
High school or less	664	641(96.5)			1			1	
Advanced	153	150(98.0)	0.584(0.621)	0.346	1.79(0.532-6.054)	0.161(0.668)	0.809	1.17(0.317-4.353)	
Employment status									
Unemployed	353	342(96.9)			1			1	
Employed	463	448(96.8)	-0.040(0.403)	0.921	0.96(0.436-2.118)	-0.250(0.432)	0.562	0.77(0.334-1.814)	
Living status									
Living alone	668	650(97.3)			1			1	
Living with a partner	148	140(94.6)	-0.724 (0.435)	0.096	0.48(0.207-1.137)	-0.239(0.468)	0.610	0.78(0.314-1.971)	
Has already been									
tested for HIV									
No	81	79(97.5)			1				
Yes	735	711(96.7)	-0.288(0.745)	0.700	0.75(0.174-3.233)	0.375(0.815)	0.646	1.45(0.295-7.180)	
Type of Self Testing									
device									
Mylan	265	249(94.0)			1			1	
Chembio	280	274(97.9)	1.077**(0.487)	0.027	2.93(1.131-7.617)	1.044**(0.497)	0.036	2.83(1.072-7.520)	
Abbott	272	268(98.5)	1.460**(0.574)	0.010	4.30(1.420-13.053)	1.349**(0.576)	0.019	3.85(1.246-11.908)	

#### **Table IV:** Factors associated with successful completion of all stages of blood self-testing

247 N: total number of subjects in univariate analysis; n: number of subjects in category; %: percentage; B: regression coefficient; SE: standard error; P: significance level; \*: <0.01;

248 \*\* <0.05; OR: Crude Odds Ratio; aOR: adjusted Odds Ratio; 95% CI: 95% confidence interval for the Odds Ratio; N2: total number of subjects in multivariate analysis

# 249 **Discussion**

250 The HIV epidemic in Cameroon is widespread among key populations such as sex workers and men who have sex with men, with national prevalence rates of 5.6% and 10.4% respectively. 251 The Cameroon government is committed to achieving the UNAIDS 95-95-95 targets and to 252 putting an end to AIDS by 2030. Innovations in HIV testing, namely testing by a non-253 professional provider and self-testing, have been implemented in Cameroon since 2015 (when 254 community-based testing was validated by CBOs) and 2022, respectively, with the aim of 255 256 increasing access to routine services for people who have not been reached yet. Available data in Cameroon shows that these screening innovations are effective in reaching undiagnosed 257 people, those getting screened for the first time or those who would not like to get screened or 258 come to health facilities as well (Spectrum programmatic data). The aim of this study was to 259 assess whether blood-based HIV testing kits could be used appropriately by unassisted non-260 261 professionals in a context of low HIV prevalence in Cameroon. The ease of use of blood-based HIV tests by non-professional users raised concerns about the potentially infectious nature of 262 waste from the procedure compared with oral fluid-based HIV self-tests. The results of this 263 study confirmed that unassisted blood-based HIV self-testing was perfectly feasible and that 264 the success of self-testing was significantly associated with the fact of being MSM and with 265 brand too. Indeed, the Abbott self-test had a 223% and MSM a 491% greater chance of passing 266 the steps involved in carrying out the test, compared with Mylan and FSWs respectively. In the 267 same vein, these results are similar to those of previous studies on HIV blood screening kits 268 conducted in the Democratic Republic of the Congo, Thailand, Central African Republic and 269 South Africa and Canada [3, 5, 14-16]. The study showed no association with employment 270 status unlike Bao, Majam, Green, Tran, Hung, Anh Luong Que et al.[17] who found an inverse 271 272 association between the type of self-test and self-test success. The proportion of MSM who had never been tested for HIV prior to this study was 17.9%, which is more than three times higher 273 than that found among MSM in Nairobi [18] but half lower than that found in Canada among 274

student population [19]. Despite the feasibility of blood-based HIV self-tests, the study revealed 275 errors in the process of obtaining the blood sample or transferring it to the test well, failure to 276 dispose of waste according to the instructions, and incorrect positioning of the device; these 277 278 errors suggest the need to modify current rules so as to make the use of self-tests easier and easier These findings confirm those of previous studies in which most errors occurred during 279 the sample collection stage by users of finger-prick HIV tests [15-17, 19]. It is worth mentioning 280 that Abbott recorded the fewest errors. It was also found that the correct interpretation of HIV 281 self-test blood test results by non-professional users was, based on the 95% confidence intervals 282 of Cohen's Kappa statistic, very low to low, low to moderate and moderate to high for Mylan, 283 Chembio and Abbott respectively, compared with interpretation by trained healthcare staff. 284 This suggests that Abbott is probably appropriate for use in key populations on an unassisted 285 basis. Difficulties in interpreting results have also been reported in the literature, with 286 differences between the different approaches [3-5, 14,20]. A systematic review reported that in 287 studies using the unassisted approach, reactive results were often misinterpreted as non-reactive 288 [20]. Misinterpretation of positive results could have a negative impact on the control of the 289 HIV epidemic [21], as HIV self-testing is considered a triage test [1, 22]. 290

# 291 Conclusion

This study showed a high level of usability (98%) of HIV blood self-tests among key 292 populations (MSM and FSWs) in the cities of Yaoundé and Douala. Despite the fact that 293 usability was restricted by results related issues and inappropriacy of waste disposal by key 294 populations, the Abbott blood self-test, with a moderate agreement, proved suitable for 295 unassisted use in key populations. These results are essential as they could help promote the 296 spread of blood-based HIV testing in addition to oral fluid-based HIV testing so as to offer a 297 298 greater choice of products to potential testees, thereby increasing uptake of HIV testing and access to essential HIV prevention such as pre-exposure prophylaxis (PrEP) and treatment 299 300 services. The COVID-19 pandemic has made access to a range of affordable blood- and oral fluid-based HIV tests more crucial than ever. Given the fact that restrictions are gradually lifted 301 and people are more and more getting access to safe and personal care, HIV self-tests are an 302

303 essential tool for accelerating catch-up HIV testing among the plethora of people who have not

304 benefited from it yet.

# 305 Acknowledgments

We are grateful to all the study participants for their contributions. We would also like to express our gratitude to Mohammed Majam, for his collaboration and commitment in implementing the study. We also thank Cameroon's Ministry of Public Health (MoPH), Population Service International (PSI) - STAR Project and Cameroon Social Marketing Association, Cameroon (ACMS) for providing the necessary and accurate resources.

# 311 **References**

312 [1] OMS. Lignes directrices sur l'autodépistage du VIH et la notification aux partenaires :

313 supplément aux lignes directrices unifiées sur les services de dépistage du VIH [Guidelines on

HIV selftesting and partner notification: supplement to consolidated guidelines on HIV testing
services]. 2018. Genève. https://creativecommons.org/licenses/by-nc-sa/3.0/igo/

316 [2] World Health Organization & UNITAID. Technology Landscape, HIV rapid diagnostic

tests for self-testing, December 2016, Semi-annual update. Geneva : WHO & UNITAID, 2016.

- http://www.who.int/hiv/pub/vct/hiv-self- testing-2016-december-edition/en/ (last access March
  2017).
- [3] Grésenguet G, Longo JD, Tonen-Wolyec S, Mboumba Bouassa RS, Belec L. Acceptability
  and Usability Evaluation of Finger-Stick Whole Blood HIV Self-Test as An HIV Screening
  Tool Adapted to The General Public in The Central African Republic. Open AIDS J. 2017;
- 323 11:101-118
- [4] Tonen-Wolyec S, Batina-Agasa S, Longo JDD, Mboumba Bouassa RS, Bélec L. Insucient
  education is a key factor of incorrect interpretation of HIV self-test results by female sex
  workers in Democratic Republic of the Congo: a multicenter cross-sectional study. Medicine.
  2019 Feb;98(6):e14218.
- 328 [5] Tonen-Wolyec S, Batina-Agasa S, Muwonga J, Mboumba Bouassa R-S, Kayembe
   329 Tshilumba C, Bélec L. Acceptability, feasibility, and individual preferences of blood based HIV
- self-testing in a population-based sample of adolescents in Kisangani, Democratic Republic of
- the Congo. PLoS One. e0218795;14(7).

- [6] Institut National de la Statistique et ICF International. Rapport de l'Enquête Démographique
- et de Santé et à indicateurs multiples du Cameroun 2016. 2018. Calverton, Maryland, USA :
- INS et ICF International https://dhsprogram.com/pubs/pdf/fr260/fr260.pdf
- [7] Comité National de lutte contre le SIDA. (2017); 2016 Integrated Biological and Behavioral
- 336 Survey (IBBS) Report among Key Populations in Cameroon : Female sex workers and men
- 337 who have sex with men
- 338 [8] Holland CE, Papworth E, Billong SC, Kassegne S, Petitbon F, Mondoleba V, et al. (2015)
- 339 Access to HIV Services at Non-Governmental and Community-Based Organizations among
- 340 Men Who Have Sex with Men (MSM) in Cameroon: An Integrated Biological and Behavioral
- 341SurveillanceAnalysis.PLoSONE10(4):e0122881.
- 342 <u>https://doi.org/10.1371/journal.pone.0122881</u>
- 343 [9] Billong SC, Eyebe S, Mossus T, Njindam Mfochive I, Tamoufe U, Fako G, Baral S, Zoung-
- 344 Kanyi AC, Kamgno J.Feasibility of demedicalization of HIV diagnosis in Cameroon:
- experimentation with HIV self-test in "key populations". Health Sci. Dis: Vol 22 (2) February
- 346 2021 pp 23-27
- 347 [10] Stanley Lemeshow S, Hosmer DWJr, Klar J and Lwanga SJ. Adequacy of Sample Size in
- Health Studies. WHO, published by John Wiley & sons, 1991
- [11] WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: CheckNOW
   HIV SELF TEST WHO reference number: PQDx 0481-032-00. 2022. available on
   https://extranet.who.int/pgweb/WHOPR/public-report-checknow-hiv-self-tespqdx-0481-032-
- 352 <u>00</u>
- [12] WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: SURE CHECK
   HIV SELF TEST WHO reference number: PQDx 0054-006-01. 2019. available on
   <u>https://extranet.who.int/pqweb/content/public-report-sure-check-hiv-self-testpqdx-0054-006-</u>
   01
- [13] WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: MYLAN HIV
   SELF TEST WHO reference number: PQDx 0320-090-00. 2019. available on
   <u>https://extranet.who.int/pqweb/content/public-report-mylan-hiv-self-testpqdx-0320-090-00</u>
- 360 [14] Tonen-Wolyec S, Tshilumba CK, Batina-Agasa S, Djang'eing'a RM, Hayette MP, Bélec
- 361 L. Comparison of practicability and effectiveness between unassisted HIV self-testing and
- 362 directly assisted HIV self-testing in the Democratic Republic of the Congo: a randomized
- 363 feasibility trial. BMC Infect Dis. 2020 Nov 11;20(1):830. pmid:3317670
- 364 [15] Smith P, Wallace M, Bekker LG. Adolescents' experience of a rapid HIV self-testing
- 365 device in youth-friendly clinic settings in Cape Town South Africa: a cross-sectional
- 366 community based usability study. Journal of the International AIDS Society 2016, 19:21111
- 367 <u>http://dx.doi.org/10.7448/IAS.19.1.21111</u>

- 368 [16] Galli RA, Tian JMLH, Sumner-Williams M, McBain K, Stanizai E, Tharao W, et al. An
- 369 observed, prospective field study to evaluate the performance and acceptance of a blood-based
- HIV self-test in Canada. BMC Public Health. 2021;21:1421. https://doi.org/10.1186/s12889-

371 <u>021-11418-z. pmid:34275450</u>

- 372 [17] Ngoc BV, Majam M, Green K, Tran T, Hung MT, Que AL, et al. (2023) Acceptability,
- feasibility, and accuracy of blood-based HIV self-testing: A cross-sectional study in Ho Chi
- 374 Minh City, Vietnam. PLOS Glob Public Health. 2023 3(2): e0001438.
  375 https://doi.org/10.1371/journal.pgph.0001438
- 376 [18] Ndungu K, Gichangi P, Temmerman M (2023) Evaluation of factors associated with HIV
- 377 self-testing Acceptability and Uptake among the MSM community in Nairobi, Kenya: A cross
- 378 sectional study. PLoS ONE 18(3): e0280540. <u>https://doi.org/10.1371/journal.pone.0280540</u>
- 379 [19] Pant Pai, N., Bhargava, M., Joseph, L., Sharma, J., Pillay, S., Balram, B., & Tellier, P.-P.
- 380 (2014). Will an Unsupervised Self-Testing Strategy Be Feasible to Operationalize in Canada?
- 381 Results from a Pilot Study in Students of a Large Canadian University. AIDS Research and
- 382 *Treatment, 2014, 1–8.* doi:10.1155/2014/747619
- 383 [20] Figueroa C, Johnson C, Ford N, Sands A, Dalal S, Meurant R, et al. Reliability of HIV
- rapid diagnostic tests for self-testing performed by self-testers compared to health-care workers:
- a systematic review and meta-analysis. Lancet HIV. 2018; 5(6):e277-e290.
- 386 [21] Prazuck, Karon, Gubavu, Andre, Legall, Bouvet, et al. A finnger-stick whole-blood HIV
- self test as an HIV screening tool adapted to the general public. PloS One. 2016;
  11(2):e0146755.
- 389 [22] World Health Organization [WHO]. HIV Self-Testing Strategic Framework: A Guide For
- Planning, Introducing And Scaling Up HIV Testing Services. Geneva 2018.